» Articles » PMID: 3014519

Design of Potent, Orally Effective, Nonpeptidal Antagonists of the Peptide Hormone Cholecystokinin

Overview
Specialty Science
Date 1986 Jul 1
PMID 3014519
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

We describe the design and synthesis of nonpeptidal antagonists of the peptide hormone cholecystokinin. Several of these compounds have high specificity and nanomolar binding affinity and are active after oral administration. To our knowledge, the design of such agents has not previously been accomplished for any peptide hormone. The structural similarities between these synthetic compounds and the anxiolytic 1,4-benzodiazepines are noted, and the potential of this structural feature for future design of ligands for other peptide hormone receptors is discussed.

Citing Articles

Structures of the human cholecystokinin receptors bound to agonists and antagonists.

Zhang X, He C, Wang M, Zhou Q, Yang D, Zhu Y Nat Chem Biol. 2021; 17(12):1230-1237.

PMID: 34556863 DOI: 10.1038/s41589-021-00866-8.


Structural simplification: an efficient strategy in lead optimization.

Wang S, Dong G, Sheng C Acta Pharm Sin B. 2019; 9(5):880-901.

PMID: 31649841 PMC: 6804494. DOI: 10.1016/j.apsb.2019.05.004.


Privileged diazepine compounds and their emergence as bromodomain inhibitors.

Smith S, Sanchez R, Zhou M Chem Biol. 2014; 21(5):573-83.

PMID: 24746559 PMC: 4035449. DOI: 10.1016/j.chembiol.2014.03.004.


Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.

Hadac E, Dawson E, Darrow J, Sugg E, Lybrand T, Miller L J Med Chem. 2006; 49(3):850-63.

PMID: 16451051 PMC: 2528300. DOI: 10.1021/jm049072h.


Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on cerulein-stimulated pancreatic exocrine secretion.

Watanabe N, Otsuki M Int J Pancreatol. 1993; 13(2):129-37.

PMID: 8501354 DOI: 10.1007/BF02786081.


References
1.
Bell S, McCaully R, GOCHMAN C, CHILDRESS S, GLUCKMAN M . 3-substituted 1,4-benzodiazepin-2-ones. J Med Chem. 1968; 11(3):457-61. DOI: 10.1021/jm00309a010. View

2.
Chang R, Lotti V . Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci U S A. 1986; 83(13):4923-6. PMC: 323856. DOI: 10.1073/pnas.83.13.4923. View

3.
Hester Jr J, RUDZIK A, Kamdar B . 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines which have central nervous system depressant activity. J Med Chem. 1971; 14(11):1078-81. DOI: 10.1021/jm00293a015. View

4.
Sunjic V, Kuftinec J, Kajfez F . Chiral 1,4-benzodiazepine. VII. Cyclization rates of 2-(n-alpha-ammoniumacyl)-amino-5-chloro-benzophenones in the chiral 1,4-benzodiazepin-2-ones. Arzneimittelforschung. 1975; 25(3):340-3. View

5.
Hughes J, Smith T, KOSTERLITZ H, Fothergill L, Morgan B, Morris H . Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 1975; 258(5536):577-80. DOI: 10.1038/258577a0. View